Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

In silico studies of medicinal compounds against hepatitis C capsid protein from north India.

Mathew S, Faheem M, Archunan G, Ilyas M, Begum N, Jahangir S, Qadri I, Qahtani MA, Mathew S.

Bioinform Biol Insights. 2014 Jun 23;8:159-68. doi: 10.4137/BBI.S15211. eCollection 2014.

PMID:
25002815
[PubMed]
Free PMC Article
2.

A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.

Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H.

Integr Cancer Ther. 2014 Jan;13(1):46-53. doi: 10.1177/1534735413490798. Epub 2013 Jun 11.

PMID:
23757319
[PubMed - in process]
Free PMC Article
3.

Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.

Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D, Cremer PS, Chen Z.

Antimicrob Agents Chemother. 2013 Jun;57(6):2571-81. doi: 10.1128/AAC.02593-12. Epub 2013 Mar 25.

PMID:
23529728
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Interplay between Hepatitis C Virus and Redox Cell Signaling.

Ruggieri A, Anticoli S, Nencioni L, Sgarbanti R, Garaci E, Palamara AT.

Int J Mol Sci. 2013 Feb 26;14(3):4705-21. doi: 10.3390/ijms14034705.

PMID:
23443167
[PubMed]
Free PMC Article
5.

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, Moradpour D, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V.

Hepatology. 2013 Mar;57(3):953-63. doi: 10.1002/hep.26260. Epub 2013 Feb 7.

PMID:
23322644
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Enhanced bioactivity of silybin B methylation products.

Sy-Cordero AA, Graf TN, Runyon SP, Wani MC, Kroll DJ, Agarwal R, Brantley SJ, Paine MF, Polyak SJ, Oberlies NH.

Bioorg Med Chem. 2013 Feb 1;21(3):742-7. doi: 10.1016/j.bmc.2012.11.035. Epub 2012 Dec 5.

PMID:
23260576
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Polyak SJ, Ferenci P, Pawlotsky JM.

Hepatology. 2013 Mar;57(3):1262-71. doi: 10.1002/hep.26179. Review. No abstract available.

PMID:
23213025
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Hepatitis C virus and natural compounds: a new antiviral approach?

Calland N, Dubuisson J, Rouillé Y, Séron K.

Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197. Review.

PMID:
23202460
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Chatterjee A, Guedj J, Perelson AS.

Antivir Ther. 2012;17(6 Pt B):1171-82. doi: 10.3851/IMP2428. Epub 2012 Oct 5. Review.

PMID:
23186606
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Hepatitis C viral kinetics: the past, present, and future.

Chatterjee A, Smith PF, Perelson AS.

Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003. Review.

PMID:
23177280
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Absolute configuration of isosilybin A by X-ray crystallography of the heavy atom analogue 7-(4-Bromobenzoyl)isosilybin A.

Sy-Cordero AA, Day CS, Oberlies NH.

J Nat Prod. 2012 Nov 26;75(11):1879-81. doi: 10.1021/np3005369. Epub 2012 Nov 1.

PMID:
23116206
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Silymarin for HCV infection.

Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM.

Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25. Review.

PMID:
23011959
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.

Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M.

Hepat Mon. 2012 Jun;12(6):411-4. doi: 10.5812/hepatmon.6135. Epub 2012 Jun 30.

PMID:
22879832
[PubMed]
Free PMC Article
14.

Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ.

PLoS One. 2012;7(7):e41832. doi: 10.1371/journal.pone.0041832. Epub 2012 Jul 25. Erratum in: PLoS One. 2012;7(10). doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458. Stamatatos, Leonidis [corrected to Stamatatos, Leonidas].

PMID:
22848626
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Modeling natural anti-inflammatory compounds by molecular topology.

Galvez-Llompart M, Zanni R, García-Domenech R.

Int J Mol Sci. 2011;12(12):9481-503. doi: 10.3390/ijms12129481. Epub 2011 Dec 20.

PMID:
22272145
[PubMed - in process]
Free PMC Article
16.

Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS.

J Hepatol. 2012 May;56(5):1019-24. doi: 10.1016/j.jhep.2011.12.012. Epub 2012 Jan 13.

PMID:
22245888
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.

Dahari H, Guedj J, Perelson AS.

Hepatology. 2011 Aug;54(2):749. doi: 10.1002/hep.24310. Epub 2011 Jun 27. No abstract available.

PMID:
21433039
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk